Insulet Co. (NASDAQ:PODD) Shares Acquired by Massmutual Trust Co. FSB ADV

Massmutual Trust Co. FSB ADV raised its position in shares of Insulet Co. (NASDAQ:PODD) by 159.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 254 shares of the medical instruments supplier’s stock after acquiring an additional 156 shares during the quarter. Massmutual Trust Co. FSB ADV’s holdings in Insulet were worth $51,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in PODD. Sunbelt Securities Inc. acquired a new stake in shares of Insulet in the first quarter valued at approximately $29,000. Benjamin F. Edwards & Company Inc. purchased a new position in Insulet during the fourth quarter worth approximately $34,000. Jones Financial Companies Lllp purchased a new position in Insulet during the fourth quarter worth approximately $40,000. Lindbrook Capital LLC lifted its position in Insulet by 64.1% during the fourth quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock worth $42,000 after buying an additional 75 shares in the last quarter. Finally, Turtle Creek Wealth Advisors LLC purchased a new position in Insulet during the fourth quarter worth approximately $43,000.

Wall Street Analyst Weigh In

A number of brokerages recently commented on PODD. OTR Global reiterated a “mixed” rating on shares of Insulet in a research report on Monday, June 10th. Barclays reduced their price objective on Insulet from $213.00 to $200.00 and set an “equal weight” rating on the stock in a research report on Monday, May 13th. Raymond James reduced their price objective on Insulet from $218.00 to $213.00 and set an “outperform” rating on the stock in a research report on Friday, May 10th. Wolfe Research upgraded Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price objective on the stock in a research report on Tuesday, May 7th. Finally, Redburn Atlantic assumed coverage on Insulet in a research note on Thursday, May 30th. They set a “buy” rating and a $235.00 target price for the company. Four research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $239.18.

Insulet Trading Up 3.0 %

Shares of NASDAQ PODD opened at $196.35 on Wednesday. Insulet Co. has a twelve month low of $125.82 and a twelve month high of $265.69. The company has a current ratio of 3.74, a quick ratio of 2.75 and a debt-to-equity ratio of 1.72. The stock has a fifty day simple moving average of $195.32 and a 200-day simple moving average of $184.05. The stock has a market capitalization of $13.75 billion, a PE ratio of 59.50, a PEG ratio of 3.55 and a beta of 1.16.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.34. Insulet had a return on equity of 34.06% and a net margin of 13.14%. The business had revenue of $441.70 million during the quarter, compared to analysts’ expectations of $424.05 million. During the same period in the previous year, the firm posted $0.23 earnings per share. The company’s revenue was up 23.3% on a year-over-year basis. On average, equities analysts forecast that Insulet Co. will post 3.11 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Mark N. Field sold 1,500 shares of the business’s stock in a transaction on Friday, June 14th. The stock was sold at an average price of $199.96, for a total transaction of $299,940.00. Following the completion of the transaction, the senior vice president now directly owns 12,875 shares of the company’s stock, valued at approximately $2,574,485. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, SVP Mark N. Field sold 1,500 shares of the business’s stock in a transaction on Friday, June 14th. The stock was sold at an average price of $199.96, for a total transaction of $299,940.00. Following the completion of the transaction, the senior vice president now directly owns 12,875 shares of the company’s stock, valued at approximately $2,574,485. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Timothy J. Scannell sold 3,300 shares of the business’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $180.90, for a total value of $596,970.00. Following the transaction, the director now directly owns 42,586 shares of the company’s stock, valued at $7,703,807.40. The disclosure for this sale can be found here. Insiders sold 13,931 shares of company stock valued at $2,636,286 in the last three months. 0.47% of the stock is owned by corporate insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.